Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for 225Ac radioimmunotherapy applications

Bioconjugate Chemistry

Volumn 11, Issue 4, 2000, Pages 510-519

  Chappell, Lara L ^a,b   Deal, Kim A ^a,c   Dadachova, Ekaterina ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b STATE UNIVERSITY OF NEW YORK AT OSWEGO   (United States)

^c CNA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODIES;

BI-FUNCTIONAL; BIFUNCTIONAL CHELATING AGENT; HALF LIVES; IN-VIVO; PROPERTY; RADIOIMMUNOTHERAPY; RADIOLABELLING; SERUM STABILITY; STABILITY STUDY; VIVO APPLICATIONS;

CHELATION;

ANIMALIA; BOS TAURUS;

EID: 0033879250     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc990153f     Document Type: Article

References (43)

1. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. 49, 2807-2813.
2. (b) Paganelli G., Grana C., Chino, M., Cremonesi, M., De Cicco, C., De Braud, F., Robertson, C., Zurrida, S., Casadio, C., Zoboli, S., Siccardi, A. G., and Veronesi, U. (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med. 26, 348-357.
3. 177Lu-CC49: A Phase I/II Study. Gyn. Oncol. 65, 94-101.
4. 67Cu-2IT-BAT-LYM-1 for Fractionated Radioimmunotherapy of Non-Hodgkin's Lymphopma: A Pilot Study. Anticancer Res. 18, 2779-2788.
5. Srivastava, S. C. (1996) Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Cancer Biother. Radiopharm. 11, 43-50.
6. McDevitt, M. R., Sgouros, G., Finn, R. D., Humm, J. L., Jurcic, J. G., Larson, S. M., and Scheinberg, D. A. (1998) Radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. 25, 1341-1351.
7. Waldmann, T. A., White, J. D., Carrasquillo, J. A., Reynolds, J. C., Paik, C. H., Gansow, O. A., Brechbiel, M. W., Jaffe, E. S., Fleisher, T. A., Goldman, C. K., Top, L. E., Bamford, R., Zaknoen, S., Roessler, S., Kasten-Sportes, C., Englang, R., Litou, H., Johnson, J. A., Jackson-White, T., Manns, A., Hanchard, B., Junghans, R. P., and Nelson, D. L. (1995) Radioimmunotherapy of IL-2Ra-Expressing Adult T-cell Leukemia with Yttrium-90 Labeled Anti-Tac. Blood 86, 4063-4075.
8. O'Donoghue, J. A., Bardies, M., and Wheldon, T. E. (1995) Relationships between Tumor Size and Curability for Uniformly Targeted Therapy with Beta-Emitting Radionuclides. J. Nucl. Med. 36, 1902-1909.
9. Jurcic, J. G., Caron, P. C., and Scheinberg, D. A. (1995) Monoclonal Antibody Therapy of Leukemia and Lymphoma. In Advances in Pharmacology (J. T. August, M. W. Anders, F. Murad, J. T. Coyle, Eds.) Vol. 33, pp 287-314, Academic Press, Inc., New York.
10. 213Bi - an α-particle emitter. Nucl. Med. Biol. 25, 241-246.
11. Nikula, T. K., McDevitt, M. R., Finn, R. D., Wu, C., Kozak, R. W., Garmestani, K, Brechbiel, M. W., Curcio, M. J., Pippin, C. G., Tiffany-Jones, L., Geerlings, M. W., Sr., Apostolidos, C., Molinet, R., Geerlings, M. W., Jr., Gansow, O. A., and Scheinberg, D. A. (1999) Alpha-Emitting Bismuth Cyclohexylbenzyl DTPA Constructs of Recombinant Humanized Anti-CD33 Antibodies: Pharmacokinetics, Bioactivity, Toxicity and Chemistry. J. Nucl. Med. 40, 166-176.
12. (a) Zalutsky, M. R., McLendon, R. E., Garg, P. K., Archer, G. E., Schuster, J. M., and Bigner, D. D. (1994) Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate. Cancer Res. 54, 4719-4725.
13. 2 fragments with the α-particle emitting nuclide astatine-211: Preservation of the immunoreactivity and in vivo localization capacity. Proc. Natl. Acad. Sci. 86, 7149-7153.
14. th National Meeting of the American Chemical Society, Dallas, TX.
15. (11 ) Zalutsky, M. R., Akabani, G., Cokgor, I., Friedman, H. S., Coleman, R. E., Friedman, A. H., McLendon, R. E., Reist, C. J., Pegram, C. N., Zhao, X.-G., and Bigner, D. D. (1998) Phase I trial of astatine-211 labeled human/mouse chimeric anti-tenascin antibody administered into malignant brain tumor resection cavities. Society of Neuro-Oncology Annual Meeting, San Francisco, CA. Neuro-Oncology 1, S65-S66.
16. 225Ac as a source of α-particles in radioimmunotherapy. Nucl. Med. Commun. 14, 121-125.
17. (b) Geerlings, M. W., and Kaspersen F. M. Radioimmunotherapy using α-particles emission. U.S. Patent 5,246,691.
18. 225Actinium Chelates: Tissue Distribution and Radiotoxicity. Nucl. Med. Biol. 26, 581-589.
19. Gansow, O. A. (1991) Newer Approaches to the Radiolabeling of Monoclonal Antibodies by the Use of Metal Chelates. Nucl. Med. Biol. 18, 369-381.
20. (a) Makarova, T. P., Sinitsyna, G. S., Stepanov, A. V., Shestakova, I. A., and Shestkov, B. I. (1972) Determination of the Complex Formation of Actinium 1. Determination of the Stability constants of Ethylenediaminetetraacetate Complexes of Actinium and its Separation from Lanthanum in Solutions of EDTA by the Method of Electromigration. Radiochimiya 14, 538-541.
21. (b) Beyer, G. J., Offord, R. E., Kunzi, G., Jones, R. M. L., Ravin, U., Aleksandrova, Yu., Werlen, R. C., Macke, H., Lindroos, M., Jahn, S., and Tengblad, D. (1995) Biokinetics of Monoclonal Antibodies Labeled with Radio-Lanthanides and 225-Ac in Xenografted Nude Mice. J. Labelled Cmpd. Radiopharm. 37, 529-530.
22. (a) Chen, X., Ji, M., Fisher, D. R., and Wai, C. M. (1998) Carboxylate-derived calixarenes with high selectivity for actinium-225. Chem. Commun. 377-378.
23. (b) Gansey, M. H. B. G., de Haan, A. S., Bos, E. S., Verboom, W., and Reinhoudt, D. N. (1999) Conjugation, Immunoreactivity, and Immunogenicity of Calix[4]arenes; Model Study to Potential Calix[4]-arene-Based Ac3+ Chelators. Bioconjugate Chem. 10, 613-623.
24. Deal, K. A., Davis, I. A., Mirzadeh, S., Kennel, S. J., and Brechbiel, M. W. (1999) Improved In Vivo Stability of Actinium-225 Macrocyclic Complexes. J. Med. Chem. 42, 2998-2992.
25. Durbin, P. W. (1960) Metabolic characteristics within a chemical family. Health Phys. 2, 225-238.
26. Kennel, S. J., personal communication.
27. Brechbiel, M. W., Gansow, O. A., Atcher, R. W., Schlom, J., Esteban, J., Simpson, D. E., and Colcher, D. (1986) Synthesis of 1-(p-Isothiocyanatobenzyl) Derivatives of DTPA and EDTA. Antibody Labeling and Tumor-Imaging Studies. lnorg. Chem. 25, 2772.
28. McMurry, T. J., Brechbiel, M. W., Kumar, K., and Gansow, O. A. (1992) Convenient Synthesis of Bifunctional Tetraaza Macrocycles. Bioconjugate Chem. 3, 108-117.
29. (a) Muraro, R., Kuroki, M., Wunderlich, D., Poole, D. J., Colcher, D., Thor, A., Greiner, J. W., Simpson, J. F., Molinolo, A., Noguchi, P., and Schlom, J. (1988) Generation and characterization of B72.3 second generation monoclonal antobodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res. 48 ,4588-4596.
30. (b) Colcher D., Esteban, J. E., Carrasquillo, J. A., Sugarbaker, P., Reynolds, J. C., Bryant, G., Larson, S. M., and Schlom, J. (1987) Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res. 47, 4218-4224.
31. Carrasquillo, J. A., Raynolds, J. C., Bunn, P. A., Foon, K. A., Shuke, N., Schroff, R. W., Mulshine, J. L., Perentesis, P., Szymendera, J., Horowitz, M., and Larson, S. M. (1993) Pharmacokinetics of In-111 T101 (Anti-CD5) Monoclonal Antibody in Patients with Cutaneous T-Cell Lymphoma. Antibody, Immunoconjugates, Radiopharm. 6, 111-126.
32. Lowry O. H., Rosebrough N. J., Farr A., and Randall A. J. (1951) Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265-275.
33. Dadachova, E., Chappell, L. L., and Brechbiel, M. W. (1999) Spectrophotometric Method for Determination of Bifunctional Macrocyclic Ligands in Macrocyclic Ligand-Protein Conjugates. Nucl. Med. Biol. 26, 977-982.
34. Schumann, H., Bottger, U. A., Zietzke, K., Hemling, H., Kociok-Kohn, G., Pickardt, J., Hahn, F. E., Zschunke, A., Schiefner, B., Gries, H., Raduchel, B., and Platzek, J. (1997) 1,4,7,10,13,16,19,22-Octaazacyclotetracosane-1,4,7,10,13, 16,19,22-octaacetic acid (H(8)OTEC) and 1,4,7,10,14,17, 20,23-octaazacyclohexacosane-1,4,7,10,14,17,20,23-octaacetic acid (H(8)OHEC): Synthesis and characterization of two large macrocyclic polyamine polycarboxylic ligands and some of their copper(II) and lanthanide(III) complexes. Chem. Ber.-Rec. 130, 267-277.
35. (a) Srivastava, S. C., Mausner, L. F., Mease, R. C., Meinken, G. E., Joshi, V., Kolsky, K., Sweet, M., and Steplewski, Z. (1995) Development and evaluation of copper-67 and samarium-153 labeled conjugates for tumor radioimmunotherapy. Int. J. Pharmacog. 33, 92-101.
36. (b) Lewis, M. R., and Shively, J. E. (1998) Maleimidocysteineamido-DOTA Derivatives: New Reagents for Radiometal Chelate Conjugation to Antibody Sulfhydryl Groups Undergo pH-Dependent Cleavage Reactions. Bioconjugate Chem. 9, 72-86.
37. Keire, D. A., and Kobayashi, M. (1999) NMR Studies of the Metal-Loading Kinetics and Acid-base Chemistry of DOTA and Butylamine-DOTA. Bioconjugate Chem. 10, 454-463.
38. 88Y(III) Complexes. J. Org. Chem. 58, 1955-1958.
39. Moi, M. K., Meares, C. F., and DeNardo, S. J. (1988) The peptide way to macrocyclic bifunctional chelating-agents -synthesis of 2-(p-nitrobenzyl)-1-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid and study of its yttrium(III) complex. J. Am. Chem. Soc. 110, 6266-6267.
40. Cox, J. P. L., Jankowski, K. J., Kataky, R., Parker, D., Beeley, N. R. A., Boyce, B. A., Eaton, M. A. W., Millar, K., Millican, At. T., Harrison, A., and Walker, C. (1989) Synthesis of a Kinetically Stable Y-90 Labeled Macrocycle antibody Conjugate. J. Chem. Soc., Chem. Commun. 797-789.
41. Atkins, T. J., Richman, J. E., and Oettlye, W. F., (1988) Macrocyclic Polyamines: 1,4,7,10,13,16-Hexaazacyclooctadecane. In Organic Synthesis Collective (W. E. Noland, Ed.) Vol. 6, pp 652-662, John Wiley & Sons: New York, 1988.
42. Shannon, R. D. (1976) Revised Effective Ionic Radii and Systematic Studies of Interatomic Distances in Halides and Chalcogenides. Acta Crystallogr. 32, 751-767.
43. Mogul, R., and Meares, C. F. (1997) Mapping an Antibody Binding Site by Nuclear Decay J. Am. Chem. Soc. 119, 7169-7170.